Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

References

• Gray JE, Villegas A, Daniel D, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020;15(2):288–293. doi:10.1016/j.jtho.2019.10.002
   PubMed Web of Science ®Google Scholar
• Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 2019;11(1):40. doi:10.1186/s13073-019-0653-7
   PubMed Web of Science ®Google Scholar
• Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. Semin Oncol. 2019;46(3):254–260. doi:10.1053/j.seminoncol.2019.07.003
   PubMed Web of Science ®Google Scholar
• Ng SP, Bahig H, Jethanandani A, et al. Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiother Oncol. 2020;145:95–100. doi:10.1016/j.radonc.2019.12.023
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ellsworth S, Campian J, et al. Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors. J Natl Compr Canc Netw. 2015;13(10):1225–1231. doi:10.6004/jnccn.2015.0151
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–5480. doi:10.1158/1078-0432.Ccr-11-0774
   PubMed Web of Science ®Google Scholar
• Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1987;139(10):3199–3206.
   PubMed Web of Science ®Google Scholar
• Stratton JA, Byfield PE, Byfield JE, Small RC, Benfield J, Pilch Y. A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients. J Clin Invest. 1975;56(1):88–97. doi:10.1172/jci108084
   PubMed Web of Science ®Google Scholar
• Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest. 2012;30(8):571–576. doi:10.3109/07357907.2012.700987
   PubMed Web of Science ®Google Scholar
• Lin AJ, Gang M, Rao YJ, et al. Association of Posttreatment Lymphopenia and Elevated Neutrophil-to-Lymphocyte Ratio With Poor Clinical Outcomes in Patients With Human Papillomavirus-Negative Oropharyngeal Cancers. JAMA Otolaryngol Head Neck Surg. 2019;145(5):413–421. doi:10.1001/jamaoto.2019.0034
   PubMed Web of Science ®Google Scholar
• Campian JL, Sarai G, Ye X, Marur S, Grossman SA. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2014;36(12):1747–1753. doi:10.1002/hed.23535
   PubMed Web of Science ®Google Scholar
• Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;105(2):346–355. doi:10.1016/j.ijrobp.2019.05.064
   PubMed Web of Science ®Google Scholar
• Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15(1):221. doi:10.1186/s12967-017-1326-1
   PubMed Web of Science ®Google Scholar
• Jabbour SK, Kim S, Haider SA, et al. Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(3):627–633. doi:10.1016/j.ijrobp.2015.02.017
   PubMed Web of Science ®Google Scholar
• Andersen PK, Klein JP, Rosthøj S. Generalised Linear Models for Correlated Pseudo-Observations, with Applications to Multi-State Models. Biometrika. 2003;90(1):15–27.
   Web of Science ®Google Scholar
• Grassberger C, Hong TS, Hato T, et al. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys. 2018;101(5):1222–1225. doi:10.1016/j.ijrobp.2018.04.026
   PubMed Web of Science ®Google Scholar
• Suzuki R, Lin SH, Wei X, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018;126(3):499–505. doi:10.1016/j.radonc.2017.12.030
   PubMed Web of Science ®Google Scholar
• Cho Y, Park S, Byun HK, et al. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019;105(5):1065–1073. doi:10.1016/j.ijrobp.2019.08.047
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Sloan L, Grossman S, Lim M. Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: a Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. Neurosurgery. 2019;85(4):441–453. doi:10.1093/neuros/nyz198
   PubMed Web of Science ®Google Scholar
• Davuluri R, Jiang W, Fang P, et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017;99(1):128–135. doi:10.1016/j.ijrobp.2017.05.037
   PubMed Web of Science ®Google Scholar
• Grewal AS, Min EJ, Long Q, et al. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy. Int J Radiat Oncol Biol Phys. 2020;106(2):358–368. doi:10.1016/j.ijrobp.2019.10.019
   PubMed Web of Science ®Google Scholar
• Contreras JA, Lin AJ, Weiner A, et al. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2018;128(3):498–504. doi:10.1016/j.radonc.2018.05.017
   PubMed Web of Science ®Google Scholar
• Joseph N, McWilliam A, Kennedy J, et al. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. Radiother Oncol. 2019;135:115–119. doi:10.1016/j.radonc.2019.03.008
   PubMed Web of Science ®Google Scholar
• MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer. 1978;41(1):108–111. doi:10.1002/1097-0142(197801)41:1<108::aid-cncr2820410116>3.0.co;2-z
   PubMed Web of Science ®Google Scholar
• McLaughlin MF, Alam M, Smith L, Ryckman J, Lin C, Baine MJ. Stereotactic body radiation therapy mitigates radiation induced lymphopenia in early stage non-small cell lung cancer. PLoS One. 2020;15(11):e0241505. doi:10.1371/journal.pone.0241505
   PubMed Web of Science ®Google Scholar
• Tang C, Liao Z, Gomez D, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014;89(5):1084–1091. doi:10.1016/j.ijrobp.2014.04.025
   PubMed Web of Science ®Google Scholar
• Xie X, Lin SH, Welsh JW, et al. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol. 2020;154:187–193. doi:10.1016/j.radonc.2020.09.002
   PubMed Web of Science ®Google Scholar
• Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(7):706–714. doi:10.1200/jco.19.01162
   PubMed Web of Science ®Google Scholar
• Jin JYHC, Xiao Y, et al. Higher radiation dose to immune system is, nonesmall cwpsipwsI, group clcAssoapc. J Med. 2017;99:S151–152.
   Google Scholar
• Ellsworth SG. Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiation Oncol. 2018;3(4):512–519. doi:10.1016/j.adro.2018.08.014
   PubMedGoogle Scholar
• Bruni A, Scotti V, Borghetti P, et al. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front Oncol. 2021;11:744956. doi:10.3389/fonc.2021.744956
   PubMed Web of Science ®Google Scholar
• Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019;21(2):206–212. doi:10.1007/s12094-018-1908-2
   PubMed Web of Science ®Google Scholar